Search

Your search keyword '"Fleischmann, R."' showing total 1,390 results
Start Over Author "Fleischmann, R."
1,390 results on '"Fleischmann, R."'

306. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Author

Furst, D.E., Keystone, E.C., Braun, J., Breedveld, F.C., Burmester, G.R., Benedetti, F. de, Dorner, T., Emery, P., Fleischmann, R., Gibofsky, A., Kalden, J.R., Kavanaugh, A., Kirkham, B., Mease, P., Sieper, J., Singer, N.G., Smolen, J.S., Riel, P.L.C.M. van, Weisman, M.H., and Winthrop, K.

Subjects
tumor-necrosis-factor systemic-lupus-erythematosus b-cell depletion placebo-controlled trial interleukin-1 receptor antagonist alpha monoclonal-antibody modifying antirheumatic drugs juvenile idiopathic arthritis randomized controlled-trials onset stills-disease
Published
2010

309. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Author

Furst, D.E., Keystone, E.C., Fleischmann, R., Mease, P., Breedveld, F.C., Smolen, J.S., Kalden, J.R., Braun, J., Bresnihan, B., Burmester, G.R., Benedetti, F. De, Dorner, T., Emery, P., Gibofsky, A., Kavanaugh, A., Kirkham, B., Schiff, M.H., Sieper, J., Singer, N., Riel, P.L.C.M. van, Weinblatt, M.E., Weisman, M.H., and Winthrop, K.

Subjects
Immunoconjugates, Tumor Necrosis Factor-alpha, Immunology, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Auto-immunity, transplantation and immunotherapy [N4i 4], General Biochemistry, Genetics and Molecular Biology, Abatacept, Antibodies, Monoclonal, Murine-Derived, Rheumatology, Evaluation of complex medical interventions [NCEBP 2], Antirheumatic Agents, Rheumatic Diseases, Immunology and Allergy, Humans, Health care ethics [NCEBP 5], Rituximab, Immunosuppressive Agents
Abstract

Contains fulltext : 87536.pdf (Publisher’s version ) (Closed access) 01 januari 2010

Published
2009

311. Avalanches of Bose–Einstein condensates in leaking optical lattices

Author

Ng, G. S., Hennig, H., Fleischmann, R., Kottos, T., and Geisel, T.

Subjects
Condensed Matter::Quantum Gases, Bose-Einstein condensates, nonlinear dynamics
Abstract

We study the decay of an atomic Bose–Einstein condensate (BEC) population N(τ) from the leaking boundaries of an optical lattice (OL). For a rescaled interatomic interaction strength Λ>Λb, discrete breathers (DBs) are created that prevent the atoms from reaching the leaking boundaries. Collisions of other lattice excitations with the outermost DBs result in avalanches, i.e. steps in N(τ), which for a whole range of Λ-values follow a scale-free distribution P(J=δN)~1/Jα. A theoretical analysis of the mixed phase space of the system indicates that 1

Published
2009

312. Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

Author

Fleischmann, R., primary, van Vollenhoven, R. F., additional, Smolen, J., additional, Emery, P., additional, Florentinus, S., additional, Rathmann, S., additional, Kupper, H., additional, Kavanaugh, A., additional, Taylor, P., additional, Genovese, M., additional, Keystone, E. C., additional, Drescher, E., additional, Berclaz, P.-Y., additional, Lee, C., additional, Fidelus-Gort, R., additional, Schlichting, D., additional, Beattie, S., additional, Luchi, M., additional, Macias, W., additional, Dikranian, A. H., additional, Alten, R., additional, Klearman, M., additional, Musselman, D., additional, Agarwal, S., additional, Green, J., additional, Gabay, C., additional, Weinblatt, M. E., additional, Schiff, M. H., additional, Fleischmann, R., additional, Valente, R., additional, van der Heijde, D., additional, Citera, G., additional, Zhao, C., additional, Maldonado, M. A., additional, Rakieh, C., additional, Nam, J. L., additional, Hunt, L., additional, Villeneuve, E., additional, Bissell, L.-A., additional, Das, S., additional, Conaghan, P., additional, McGonagle, D., additional, Wakefield, R. J., additional, Wright, H. L., additional, Thomas, H. B., additional, Moots, R., additional, Edwards, S. W., additional, Hamann, P., additional, Heward, J., additional, McHugh, N., additional, Lindsay, M. A., additional, Haroon, M., additional, Giles, J. T., additional, Winchester, R., additional, FitzGerald, O., additional, Karaderi, T., additional, Cohen, C. J., additional, Keidel, S., additional, Appleton, L. H., additional, Macfarlane, G. J., additional, Siebert, S., additional, Evans, D., additional, Paul Wordsworth, B., additional, Plant, D., additional, Bowes, J., additional, Orozco, G., additional, Morgan, A. W., additional, Wilson, A. G., additional, Isaacs, J., additional, Barton, A., additional, Williams, F. M., additional, Livshits, G., additional, Spector, T., additional, MacGregor, A., additional, Scollen, S., additional, Cao, D., additional, Memari, Y., additional, Hyde, C. L., additional, Zhang, B., additional, Sidders, B., additional, Ziemek, D., additional, Shi, Y., additional, Harris, J., additional, Harrow, I., additional, Dougherty, B., additional, Malarstig, A., additional, McEwen, R., additional, Stephens, J. L., additional, Patel, K., additional, Shin, S.-Y., additional, Surdulescu, G., additional, He, W., additional, Jin, X., additional, McMahon, S. B., additional, Soranzo, N., additional, John, S., additional, Wang, J., additional, Spector, T. D., additional, Baker, J., additional, Litherland, G. J., additional, Rowan, A. D., additional, Kite, K. A., additional, Bayley, R., additional, Yang, P., additional, Smith, J. P., additional, Williams, J., additional, Harper, L., additional, Kitas, G. D., additional, Buckley, C., additional, Young, S. P., additional, Fitzpatrick, M. A., additional, McGettrick, H. M., additional, Filer, A., additional, Raza, K., additional, Nash, G., additional, Muthana, M., additional, Davies, H., additional, Khetan, S., additional, Adeleke, G., additional, Hawtree, S., additional, Tazzyman, S., additional, Morrow, F., additional, Ciani, B., additional, Wilson, G., additional, Quirke, A.-M., additional, Lugli, E., additional, Wegner, N., additional, Charles, P., additional, Hamilton, B., additional, Chowdhury, M., additional, Ytterberg, J., additional, Potempa, J., additional, Fisher, B., additional, Thiele, G., additional, Mikuls, T., additional, Venables, P., additional, Adebajo, A. O., additional, Mease, P., additional, Gomez-Reino, J. J., additional, Wollenhaupt, J., additional, Hu, C., additional, Stevens, R., additional, Sieper, J., additional, Dougados, M., additional, Van den Bosch, F., additional, Goupille, P., additional, Rathmann, S. S., additional, Pangan, A. L., additional, Maksymowych, W. P., additional, Brown, M. A., additional, Elewaut, D., additional, Anderson, J., additional, Ramasamy, P., additional, O'Rourke, M., additional, Murphy, C., additional, Fitzgerald, O., additional, Jani, M., additional, Moore, S., additional, Mirjafari, H., additional, Macphie, E., additional, Chinoy, H., additional, Rao, C., additional, McLoughlin, Y., additional, and Preeti, S., additional

Published
2013
Full Text
View/download PDF

313. Avalanches of Bose-Einstein Condensates in Leaking Optical Lattices

Author

Ng, G. S., Hennig, H., Fleischmann, R., Kottos, T., and Geisel, T.

Subjects
Condensed Matter - Other Condensed Matter, Condensed Matter::Quantum Gases, Statistical Mechanics (cond-mat.stat-mech), FOS: Physical sciences, Chaotic Dynamics (nlin.CD), Nonlinear Sciences - Chaotic Dynamics, Condensed Matter - Statistical Mechanics, Other Condensed Matter (cond-mat.other)
Abstract

One of the most fascinating experimental achievements of the last decade was the realization of Bose-Einstein Condensation (BEC) of ultra-cold atoms in optical lattices (OL's). The extraordinary level of control over these structures allows us to investigate complex solid state phenomena and the emerging field of ``atomtronics'' promises a new generation of nanoscale devices. It is therefore of fundamental and technological importance to understand their dynamical properties. Here we study the outgoing atomic flux of BECs loaded in an one-dimensional OL with leaking edges, using a mean field description provided by the Discrete Non-Linear Schrodinger Equation (DNLSE). We demonstrate that the atom population inside the OL decays in avalanches of size $J$. For intermediate values of the interatomic interaction strength their distribution ${\cal P}(J)$ follows a power law i.e. ${\cal P}(J)\sim1/J^{\alpha}$ characterizing systems at phase transition. This scale free behaviour of ${\cal P}(J)$ reflects the complexity and the hierarchical structure of the underlying classical mixed phase space. Our results are relevant in a variety of contexts (whenever DNLSE is adequate), most prominently the light emmitance from coupled non-linear optics waveguides., Comment: 7 pages and 3 figures

Published
2008
Full Text
View/download PDF

321. Klinische Pharmakologie

Author

Czechanowski, B., primary, Baumann, R., additional, Ding, R., additional, Ebel, V., additional, Gundert-Remy, U., additional, Harenberg, J., additional, Hildebrandt, R., additional, v. Kaiz-Welle, G., additional, Schäfer, D. O., additional, Spohr, U., additional, Staiger, C., additional, Walter, E., additional, Yakpo-Wempe, C., additional, Weber, E., additional, Kramer, P., additional, Rohde, A., additional, Eisenhauer, T., additional, Isemer, F. E., additional, Hildebrand, H. H., additional, Scheler, F., additional, Mathieu, P., additional, Bowers, W. F., additional, Kolenda, K.-D., additional, Maier, Ch., additional, Kirch, W., additional, Dylewicz, P., additional, Kölbel, C., additional, Pabst, J., additional, Ohnhaus, E. E., additional, Zilly, W., additional, Drost, D., additional, Klinker, H., additional, Jöres, R., additional, Heusler, H., additional, Richter, E., additional, Kuntz, H. D., additional, Femfert, U., additional, May, B., additional, Klotz, U., additional, Reimann, I. W., additional, Kaschell, J., additional, Ochs, H. R., additional, Knüchel, M., additional, Verburg-Ochs, B., additional, Djonlagić, H., additional, Mansour, A., additional, Hackenjos, B., additional, Potratz, J., additional, Fleischmann, R., additional, Bozler, G., additional, Boekstegers, P., additional, Haas, R., additional, Südbeck, C., additional, Krause, U., additional, Beyer, J., additional, Brodde, O.-E., additional, Daul, A., additional, O’Hara, N., additional, Khalifa, A. M., additional, Bock, K. D., additional, Hasenfuß, G., additional, Knauf, H., additional, Just, H., additional, Schäfer-Korting, M., additional, Mutschler, E., additional, Weth, G., additional, Huermer, H., additional, Krebs, A., additional, Werner, Th., additional, Schneider, N., additional, Haubitz, J., additional, Brockmeyer, N., additional, Breithaupt, H., additional, Mehlburger, H., additional, Ferdinand, W., additional, von Hattingberg, M., additional, Ostrowski, J., additional, Stauch, M., additional, Voegele, D., additional, Brockmeier, D., additional, Rudolph, W., additional, Resag, K., additional, Thiery, J., additional, Seidel, D., additional, Ziegler, G., additional, Frölich, J. C., additional, Wietholtz, H., additional, Schölmerich, J., additional, Gerok, W., additional, Spahn, H., additional, Usinger, P., additional, Rupp, W., additional, Robertz, G.-M., additional, and Dengler, H. J., additional

Published
1984
Full Text
View/download PDF

324. Klinische Pharmakologie

Author

Kewitz, H., primary, Sprandel, U., additional, Hubbard, A. R., additional, Chalmers, R. A., additional, Piper, C., additional, Bonn, R., additional, Weber, E., additional, Düsing, R., additional, Nicolas, V., additional, Glänzer, K., additional, Kipnowski, J., additional, Kramer, H. J., additional, Abshagen, U., additional, Spörl-Radun, S., additional, Betzien, G., additional, Kaufmann, B., additional, Endele, R., additional, Gellert, J., additional, Frenzel, H., additional, Heidenreich, T., additional, Nishimura, M., additional, Teschke, R., additional, Schulz, V., additional, Löffler, A., additional, Pasch, T., additional, Loeschcke, G., additional, Busse, J., additional, Kemmerich, B., additional, Lode, H., additional, Belmega, G., additional, Jendroschek, T., additional, Borner, K., additional, Koeppe, P., additional, Witkowski, G., additional, Höffken, G., additional, Dzwillo, G., additional, Kuhlmann, J., additional, Seidel, G., additional, Grötsch, H., additional, Münch, L., additional, Fleischmann, R., additional, Heinrich, R., additional, Malchow, H., additional, Bozler, G., additional, Ochs, H. R., additional, Otten, H., additional, Kaschell, H. J., additional, Klehr, U., additional, Röllinghoff, W., additional, Sticken, R., additional, and Paumgartner, G., additional

Published
1981
Full Text
View/download PDF

330. Muscle disorders * 111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study

Author

Campbell, R., primary, Hofmann, D., additional, Hatch, S., additional, Gordon, P., additional, Lempp, H., additional, Das, L., additional, Blumbergs, P., additional, Limaye, V., additional, Vermaak, E., additional, McHugh, N., additional, Edwards, M. H., additional, Jameson, K., additional, Sayer, A. A., additional, Dennison, E., additional, Cooper, C., additional, Salvador, F. B., additional, Huertas, C., additional, Isenberg, D., additional, Jackson, E. J., additional, Middleton, A., additional, Churchill, D., additional, Walker-Bone, K., additional, Worsley, P. R., additional, Mottram, S., additional, Warner, M., additional, Morrissey, D., additional, Gadola, S., additional, Carr, A., additional, Stokes, M., additional, Srivastava, R. N., additional, Sanghi, D., additional, Elbaz, A., additional, Mor, A., additional, Segal, G., additional, Drexler, M., additional, Norman, D., additional, Peled, E., additional, Rozen, N., additional, Goryachev, Y., additional, Debbi, E. M., additional, Haim, A., additional, Wolf, A., additional, Debi, R., additional, Cohen, M. S., additional, Igolnikov, I., additional, Bar Ziv, Y., additional, Benkovich, V., additional, Bernfeld, B., additional, Collins, J., additional, Moots, R. J., additional, Clegg, P. D., additional, Milner, P. I., additional, Ejtehadi, H. D., additional, Nelson, P. N., additional, Wenham, C., additional, Balamoody, S., additional, Hodgson, R., additional, Conaghan, P., additional, Wilkie, R., additional, Blagojevic, M., additional, Jordan, K. P., additional, Mcbeth, J., additional, Peffers, M. J., additional, Beynon, R. J., additional, Thornton, D. J., additional, Chapman, R., additional, Chapman, V., additional, Walsh, D., additional, Kelly, S., additional, Hui, M., additional, Zhang, W., additional, Doherty, S., additional, Rees, F., additional, Muir, K., additional, Maciewicz, R., additional, Doherty, M., additional, Snelling, S., additional, Davidson, R. K., additional, Swingler, T., additional, Price, A., additional, Clark, I., additional, Stockley, E., additional, Hathway, G., additional, Faas, H., additional, Auer, D., additional, Hirsch, G., additional, Hale, E., additional, Kitas, G., additional, Klocke, R., additional, Abraham, A., additional, Pearce, M. S., additional, Mann, K. D., additional, Francis, R. M., additional, Birrell, F., additional, Tucker, M., additional, Mellon, S. J., additional, Jones, L., additional, Price, A. J., additional, Dieppe, P. A., additional, Gill, H. S., additional, Ashraf, S., additional, Walsh, D. A., additional, McCollum, D., additional, McCabe, C., additional, Grieve, S., additional, Shipley, J., additional, Gorodkin, R., additional, Oldroyd, A. G., additional, Evans, B., additional, Greenbank, C., additional, Bukhari, M., additional, Rajak, R., additional, Bennett, C., additional, Williams, A., additional, Martin, J. C., additional, Abdulkader, R., additional, MacNicol, C., additional, Brixey, K., additional, Stephenson, S., additional, Clunie, G., additional, Andrews, R. N., additional, Clark, E. M., additional, Gould, V. C., additional, Carter, L., additional, Morrison, L., additional, Tobias, J. H., additional, Pye, S. R., additional, Vanderschueren, D., additional, O'Neill, T. W., additional, Lee, D. M., additional, Jans, I., additional, Billen, J., additional, Gielen, E., additional, Laurent, M., additional, Claessens, F., additional, Adams, J. E., additional, Ward, K. A., additional, Bartfai, G., additional, Casanueva, F., additional, Finn, J. D., additional, Forti, G., additional, Giwercman, A., additional, Han, T. S., additional, Huhtaniemi, I., additional, Kula, K., additional, Lean, M. E., additional, Pendleton, N., additional, Punab, M., additional, Wu, F. C., additional, Boonen, S., additional, Mercieca, C., additional, Webb, J., additional, Bhalla, A., additional, Fairbanks, S., additional, Moss, K. E., additional, Collins, C., additional, Sedgwick, P., additional, Parker, J., additional, Harvey, N. C., additional, Cole, Z. A., additional, Crozier, S. R., additional, Ntani, G., additional, Mahon, P. A., additional, Robinson, S. M., additional, Inskip, H. M., additional, Godfrey, K. M., additional, Dennison, E. M., additional, Bridges, M., additional, Ruddick, S., additional, Holroyd, C. R., additional, Mahon, P., additional, Godfrey, K., additional, McNeilly, T., additional, McNally, C., additional, Beringer, T., additional, Finch, M., additional, Coda, A., additional, Davidson, J., additional, Walsh, J., additional, Fowlie, P., additional, Carline, T., additional, Santos, D., additional, Patil, P., additional, Rawcliffe, C., additional, Olaleye, A., additional, Moore, S., additional, Fox, A., additional, Sen, D., additional, Ioannou, Y., additional, Nisar, S., additional, Rankin, K., additional, Birch, M., additional, Finnegan, S., additional, Rooney, M., additional, Gibson, D. S., additional, Malviya, A., additional, Ferris, C. M., additional, Rushton, S. P., additional, Foster, H. E., additional, Hanson, H., additional, Muthumayandi, K., additional, Deehan, D. J., additional, Birt, L., additional, Poland, F., additional, MacGregor, A., additional, Armon, K., additional, Pfeil, M., additional, McErlane, F., additional, Beresford, M. W., additional, Baildam, E. M., additional, Thomson, W., additional, Hyrich, K., additional, Chieng, A., additional, Gardner-Medwin, J., additional, Lunt, M., additional, Wedderburn, L., additional, Newell, K., additional, Evans, A., additional, Manning, G., additional, Scaife, C., additional, McAllister, C., additional, Pennington, S. R., additional, Duncan, M., additional, Moore, T., additional, Pericleous, C., additional, Croca, S. C., additional, Giles, I., additional, Alber, K., additional, Yong, H., additional, Midgely, A., additional, Rahman, A., additional, Rzewuska, M., additional, Mallen, C., additional, Strauss, V. Y., additional, Belcher, J., additional, Peat, G., additional, Byng-Maddick, R., additional, Wijendra, M., additional, Penn, H., additional, Roddy, E., additional, Muller, S., additional, Hayward, R., additional, Kamlow, F., additional, Pakozdi, A., additional, Jawad, A., additional, Green, D. J., additional, Hider, S. L., additional, Singh Bawa, S., additional, Bawa, S., additional, Turton, A., additional, Palmer, M., additional, Lewis, J., additional, Moss, T., additional, Goodchild, C. E., additional, Tang, N., additional, Scott, D., additional, Salkovskis, P., additional, Selvan, S., additional, Williamson, L., additional, Thalayasingam, N., additional, Higgins, M., additional, Saravanan, V., additional, Rynne, M., additional, Hamilton, J. D., additional, Heycock, C., additional, Kelly, C., additional, Norton, S., additional, Sacker, A., additional, Done, J., additional, Young, A., additional, Smolen, J. S., additional, Fleischmann, R. M., additional, Emery, P., additional, van Vollenhoven, R. F., additional, Guerette, B., additional, Santra, S., additional, Kupper, H., additional, Redden, L., additional, Kavanaugh, A., additional, Keystone, E. C., additional, van der Heijde, D., additional, Weinblatt, M. E., additional, Mozaffarian, N., additional, Liu, S., additional, Zhang, N., additional, Wilkinson, S., additional, Riaz, M., additional, Ostor, A. J., additional, Nisar, M. K., additional, Burmester, G., additional, Mariette, X., additional, Navarro-Blasco, F., additional, Oezer, U., additional, Kary, S., additional, Unnebrink, K., additional, Jobanputra, P., additional, Maggs, F., additional, Deeming, A., additional, Carruthers, D., additional, Rankin, E., additional, Jordan, A., additional, Faizal, A., additional, Goddard, C., additional, Pugh, M., additional, Bowman, S., additional, Brailsford, S., additional, Nightingale, P., additional, Tugnet, N., additional, Cooper, S. C., additional, Douglas, K. M., additional, Edwin Lim, C. S., additional, Bee Lian Low, S., additional, Joy, C., additional, Hill, L., additional, Davies, P., additional, Mukherjee, S., additional, Cornell, P., additional, Westlake, S. L., additional, Richards, S., additional, Rahmeh, F., additional, Thompson, P. W., additional, Breedveld, F., additional, Keystone, E., additional, Landewe, R., additional, McIlraith, M., additional, Dharmapalaiah, C., additional, Shand, L., additional, Rose, G., additional, Watts, R., additional, Eldashan, A., additional, Dasgupta, B., additional, Borg, F. A., additional, Bell, G. M., additional, Anderson, A. E., additional, Harry, R. A., additional, Stoop, J. N., additional, Hilkens, C. M., additional, Isaacs, J., additional, Dickinson, A., additional, McColl, E., additional, Banik, S., additional, Smith, L., additional, France, J., additional, Rutherford, A., additional, Scott Russell, A., additional, Smith, J., additional, Jassim, I., additional, Withrington, R., additional, Bacon, P., additional, De Lord, D., additional, McGregor, L., additional, Morrison, I., additional, Stirling, A., additional, Porter, D. R., additional, Saunders, S. A., additional, Else, S., additional, Semenova, O., additional, Thompson, H., additional, Ogunbambi, O., additional, Kallankara, S., additional, Baguley, E., additional, Patel, Y., additional, Alzabin, S., additional, Abraham, S., additional, Taher, T. E., additional, Palfeeman, A., additional, Hull, D., additional, McNamee, K., additional, Pathan, E., additional, Kinderlerer, A., additional, Taylor, P., additional, Williams, R. O., additional, Mageed, R. A., additional, Iaremenko, O., additional, Mikitenko, G., additional, Ferrari, M., additional, Kamalati, T., additional, Pitzalis, C., additional, Pearce, F., additional, Tosounidou, S., additional, Obrenovic, K., additional, Erb, N., additional, Packham, J., additional, Sandhu, R., additional, White, C., additional, Cardy, C. M., additional, Justice, E., additional, Frank, M., additional, Li, L., additional, Lloyd, M., additional, Ahmed, A., additional, Readhead, S., additional, Ala, A., additional, Fittall, M., additional, Manson, J., additional, Sibilia, J., additional, Marc Flipo, R., additional, Combe, B., additional, Gaillez, C., additional, Le Bars, M., additional, Poncet, C., additional, Elegbe, A., additional, Westhovens, R., additional, Hassanzadeh, R., additional, Mangan, C., additional, Fleischmann, R., additional, van Vollenhoven, R., additional, Huizinga, T. W. J., additional, Goldermann, R., additional, Duncan, B., additional, Timoshanko, J., additional, Luijtens, K., additional, Davies, O., additional, Dougados, M., additional, Hewitt, J., additional, Owlia, M., additional, Schiff, M., additional, Alten, R., additional, Kaine, J. L., additional, Nash, P. T., additional, Delaet, I., additional, Qi, K., additional, Genovese, M. C., additional, Clark, J., additional, Kardash, S., additional, Wong, E., additional, Hull, R., additional, McCrae, F., additional, Shaban, R., additional, Thomas, L., additional, Young-Min, S., additional, Ledingham, J., additional, Covarrubias Cobos, A., additional, Leon, G., additional, Mysler, E. F., additional, Keiserman, M. W., additional, Valente, R. M., additional, Abraham Simon Campos, J., additional, Porawska, W., additional, Box, J. H., additional, Legerton, C. W., additional, Nasonov, E. L., additional, Durez, P., additional, Pappu, R., additional, Teng, J., additional, Edwards, C. J., additional, Arden, N., additional, Campbell, J., additional, van Staa, T., additional, Housden, C., additional, Sargeant, I., additional, Choy, E., additional, McAuliffe, S., additional, Roberts, K., additional, Sarzi-Puttini, P., additional, Andrianakos, A., additional, Sheeran, T. P., additional, Choquette, D., additional, Finckh, A., additional, Desjuzeur, M.-L., additional, Gemmen, E. K., additional, Mpofu, C., additional, Gottenberg, J.-E., additional, Shah, P., additional, Cox, M., additional, Nye, A., additional, O'Brien, A., additional, Jones, P., additional, Jones, G. T., additional, Paudyal, P., additional, MacPherson, H., additional, Sim, J., additional, Ernst, E., additional, Fisken, M., additional, Lewith, G., additional, Tadman, J., additional, Macfarlane, G. J., additional, Bertin, P., additional, Arendt, C., additional, Terpstra, I., additional, VanLunen, B., additional, de Longueville, M., additional, Zhou, H., additional, Cai, A., additional, Lacy, E., additional, Kay, J., additional, Matteson, E., additional, Hu, C., additional, Hsia, E., additional, Doyle, M., additional, Rahman, M., additional, Shealy, D., additional, Scott, D. L., additional, Ibrahim, F., additional, Abozaid, H., additional, Hassell, A., additional, Plant, M., additional, Walker, D., additional, Simpson, G., additional, Kowalczyk, A., additional, Prouse, P., additional, Brown, A., additional, George, M., additional, Kumar, N., additional, Mackay, K., additional, Marshall, S., additional, Ludivico, C. L., additional, Murthy, B., additional, Corbo, M., additional, Samborski, W., additional, Berenbaum, F., additional, Ambrugeat, J., additional, Bennett, B., additional, Burkhardt, H., additional, Bykerk, V., additional, Roman Ivorra, J., additional, Wollenhaupt, J., additional, Stancati, A., additional, Bernasconi, C., additional, Scott, D. G. I., additional, Claydon, P., additional, Ellis, C., additional, Buchan, S., additional, Pope, J., additional, Bingham, C. O., additional, Massarotti, E. M., additional, Coteur, G., additional, Weinblatt, M., additional, Ball, C., additional, Ainsworth, T., additional, Kermik, J., additional, Woodham, J., additional, Haq, I., additional, Quesada-Masachs, E., additional, Carolina Diaz, A., additional, Avila, G., additional, Acosta, I., additional, Sans, X., additional, Alegre, C., additional, Marsal, S., additional, McWilliams, D., additional, Kiely, P. D., additional, Bolce, R., additional, Wang, J., additional, Ingham, M., additional, Dehoratius, R., additional, Decktor, D., additional, Rao, V., additional, Pavlov, A., additional, Klearman, M., additional, Musselman, D., additional, Giles, J., additional, Bathon, J., additional, Sattar, N., additional, Lee, J., additional, Baxter, D., additional, McLaren, J. S., additional, Gordon, M.-M., additional, Thant, K. Z., additional, Williams, E. L., additional, Earl, S., additional, White, P., additional, Williams, J., additional, Jan, A. K., additional, Bhatti, A. I., additional, Stafford, C., additional, Carolan, M., additional, and Ramakrishnan, S. A., additional

Published
2012
Full Text
View/download PDF

335. Kernphysik

Author

Auger, P., primary, Bernardini, G., additional, Bothe, W., additional, Clay, J., additional, Cockcroft, J. D., additional, Dunning, J. R., additional, Fleischmann, R., additional, Franchetti, S., additional, Geiger, H., additional, v. Halban, H., additional, Meitner, L., additional, Oliphant, M. L. E., additional, Preiswerk, P., additional, and Williams, E. J., additional

Published
1936
Full Text
View/download PDF

338. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

Author

Yazici, Y., McAlindon, T.E., Fleischmann, R., Gibofsky, A., Lane, N.E., Kivitz, A.J., Skrepnik, N., Armas, E., Swearingen, C.J., DiFrancesco, A., Tambiah, J.R.S., Hood, J., and Hochberg, M.C.

Abstract

Objective: To assess the safety, pharmacokinetics, and exploratory efficacy of SM04690, a novel Wnt pathway inhibitor, as a potential disease modifying treatment for knee osteoarthritis (OA).Design: Subjects with Kellgren-Lawrence grade 2-3 knee OA were randomized in successive dose-escalation cohorts to receive a knee intra-articular (IA) injection with 0.03, 0.07, or 0.23 mg SM04690, or placebo (PBO) (4:1 ratio). Safety, pharmacokinetics, efficacy (WOMAC Total/Function/Pain, Pain VAS, Physician Global Assessment [MDGA], and OMERACT-OARSI Response), OA-related biomarker (P1NP, ß-CTX, and cartilage oligomeric matrix protein [COMP]), and radiographic/imaging data were collected at baseline and during 24-week follow-up.Results: 61 subjects (SM04690 n = 50; PBO n = 11) enrolled. Two dose limiting toxicities (DLTs), increased pain following injection and paroxysmal tachycardia (also the single serious AE), were reported in the 0.07 mg cohort. A total of 72 AEs were reported; Sixteen (occurring in eight subjects) were considered related to study medication. There were three discontinuations; one due to an AE (0.03 mg cohort). Bone marrow edema (BME) remained constant for most subjects. No doses were excluded from further study due to DLT criteria. Plasma levels of SM04690 were below the limit of detection at all time points. At Week 24, improvements from baseline were seen in all cohorts for the exploratory measures WOMAC Total, WOMAC Function, WOMAC Pain, MDGA, Pain VAS, and OMERACT-OARSI response. Joint space width (JSW) improvement was observed in the 0.07 mg cohort (P = 0.02 vs PBO).Conclusion: SM04690 appeared safe and well tolerated, with no evidence of systemic exposure. Exploratory efficacy analyses suggested positive trends for measurements of OA pain, function and disease-modifying osteoarthritis drug (DMOAD) properties. CLINICALTRIALS.Gov Registration: NCT02095548. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

339. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.

Author

van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., and Davies, O.

Abstract

Objective Early identification of patients unlikely to achieve good long-term disease control with anti-tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat-to-target recommendations. Here we assess associations between disease activity or clinical response during the first 12 weeks of treatment and attainment of treatment targets at week 48 in axial SpA and PsA patients receiving certolizumab pegol. Methods The relationship between disease activity or clinical response during the first 12 weeks of treatment and achievement of week-48 targets (for axial SpA: inactive disease based on Ankylosing Spondylitis Disease Activity Score [ASDAS] using the C-reactive protein [CRP] level, or Bath Ankylosing Spondylitis Disease Activity Index <2 with normal CRP level; and for PsA: minimal disease activity) was assessed post hoc using RAPID-axSpA and RAPID-PsA trial data. Results A clear relationship between disease activity from week 2 to 12 and achievement of week-48 treatment targets was observed in both axial SpA and PsA populations. In axial SpA, week-48 ASDAS inactive disease was achieved by 0% of patients (0 of 21) with ASDAS very high disease activity at week 12, compared to 68% of patients (34 of 50) with week-12 ASDAS inactive disease. For PsA, week-48 minimal disease activity was achieved by 0% of patients (0 of 26) with Disease Activity Score in 28 joints (DAS28) using the CRP level >5.1 at week 12, compared to 73% of patients (57 of 78) with DAS28-CRP <2.6. Similar results were observed regardless of the disease activity measure used. Clinical response at week 12 also predicted week-48 outcomes, though to a lesser extent than disease activity. Conclusion Using disease activity and the clinical response state during the first 12 weeks of certolizumab pegol treatment, it was possible to identify a subset of axial SpA and PsA patients unlikely to achieve long-term treatment goals. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

340. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.

Author

Fleischmann, R, Mease, PJ, Schwartzman, S, Hwang, L-J, Soma, K, Connell, CA, Takiya, L, and Bananis, E

Subjects
*DRUG efficacy, *RHEUMATOID arthritis treatment, *METHOTREXATE, *DRUG dosage, *ORAL medication, *RANDOMIZED controlled trials
Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10 mg twice daily (BID), or placebo, with low (≤12.5 mg/week), moderate (>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5 mg BID ( N = 321), tofacitinib 10 mg BID ( N = 316), or placebo ( N = 160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results